YMAB vs. SGMT

In the year-to-date period, YMAB achieves a 21.41% return, which is significantly higher than SGMT's -8.67% return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Y-mAbs Therapeutics, Inc. (YMAB) and Sagimet Biosciences Inc. (SGMT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current YMAB Sharpe Ratio is 0.48, which is higher than the SGMT Sharpe Ratio of -0.04. The chart below compares the historical Sharpe Ratios of YMAB and SGMT, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Neither YMAB nor SGMT has paid dividends to shareholders.

The maximum YMAB drawdown since its inception was -94.78%, which is greater than SGMT's maximum drawdown of -86.59%. Use the drawdown chart below to compare losses from any high point for YMAB and SGMT. For additional features, visit the drawdowns tool.

The current volatility for Y-mAbs Therapeutics, Inc. (YMAB) is 20.26%, while Sagimet Biosciences Inc. (SGMT) has a volatility of 37.26%. This indicates that YMAB experiences smaller price fluctuations and is considered to be less risky than SGMT based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Y-mAbs Therapeutics, Inc. and Sagimet Biosciences Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.